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Abstract
The burden of community-associated Clostridium difficile infection (CA-CDI) has increased.
We aimed to describe the epidemiology of CA-CDI to inform future interventions. We used
population-based linked surveillance data from 2012 to 2016 to describe socio-demographic
factors, ribotype and mortality for all CA (n = 1303) and hospital-associated (HA, n = 1356)
CDI. For 483 community-onset (CO) CA-CDI and 287 COHA-CDI cases, a questionnaire
on risk factors was completed and we conducted a case–case study using logistic regression
models for univariate and multivariable analysis. CA-CDI cases had lower odds of being
male (adjusted odds ratio (AOR) 0.71, 95% confidence interval (CI) 0.58–0.87; P < 0.001),
and higher odds of living in rural rather than urban settlement (AOR 1.5, 95% CI 1.1–2.1;
P = 0.05) compared with HA-CDI cases. The distribution of ribotypes was similar in both
groups with RT078 being most prevalent. CDI-specific death was lower in CA-CDI than
HA-CDI (7% vs. 11%, P < 0.001). COCA-CDI had lower odds of having had an outpatient
appointment in the previous 4 weeks compared with COHA-CDI (AOR 0.61; 95% CI
0.41–0.9, P = 0.01) and lower odds of being in a care home or hospice when compared
with their own home, than COHA-CDI (AOR 0.66; 95% CI 0.45–0.98 and AOR 0.35; 95%
CI 0.13–0.92, P = 0.02). Exposure to gastric acid suppressants (50% in COCA-CDI and
55% in COHA-CDI) and antimicrobial therapy (18% in COCA-CDI and 20% in COHA-
CDI) prior to CDI was similar. Our analysis of community-onset cases suggests that other
risk factors for COHA-CDI may be equally important for COCA-CDI. Opportunities to safely
reduce antibiotic and gastric acid suppressants use should be investigated in all healthcare
settings.
Introduction
Clostridium difficile infection (CDI) is recognised as a hospital-associated (HA) infection
responsible for significant morbidity and mortality [1–4]. Over the last two decades, there
has been a significant reduction in the incidence of HA-CDI across the UK [5]. The reasons
for this are multi-faceted but undoubtedly changes in prescribing and infection control beha-
viours have played a key role.
Unlike HA-CDI, the definition of community-associated (CA) CDI is more complex and
very few countries have a national surveillance programme to promote improvement based
on local intelligence. However, an increasing burden of infections that are CA has been
observed from the available data [6–8]. This in part reflects a lack of understanding about
risk factors which for CA-CDI, unlike HA-CDI [7], are still not well categorised [6, 9, 10].
This is influenced by both a relative lack of data and conflicting information about potential
risk factors, such as antibiotic use [11].
While the incidence of CA-CDI has been increasing, there is limited information about
patient outcomes. Studies on HA-CDI have identified CDI-specific mortality in the range
of 7–42% [12]. However, similar information is lacking for CA-CDI, particularly in the UK
setting. The virulence of the CDI infection is linked to the CDI ribotypes [7, 9, 13–15]. In
most of the UK, ribotyping is conducted on a subset of cases which includes a random sample
plus cases identified when an increased incidence is observed. This can skew the results
to the most virulent strain and also means that a complete picture for community CDI is lack-
ing [16].
In this study, we attempt to address these issues using a population dataset of infection and
ribotype data to compare CA- and HA-CDI to: (1) describe the epidemiology of these
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infections, (2) describe CA-CDI case fatality and ribotypes and
(3) compare risk factors for those with disease onset in the com-
munity with a view to informing preventive measures for CA
cases.
Methods
Data sources
This was a population-based data-linkage study of all individuals
with laboratory-confirmed CDI in Northern Ireland (NI) from 1
January 2012 to 31 December 2016 (n = 2807).
In 2012, the Public Health Agency (PHA) introduced an
enhanced surveillance system for community-onset (CO) CDI.
A questionnaire is completed for each CO-CDI case to collect
information on potential risk factors including demographic
data (age and sex), healthcare contact, selected medication use,
travel history and infant contact. The CO-CDI dataset is matched
to CDI infections reported to the PHA from Trust laboratories
(n = 5) to produce a full population combined dataset of commu-
nity and hospital onset cases. There are currently no private
microbiology laboratories in NI. Ribotype information is available
for the entire dataset.
For this study, the combined dataset was linked deterministic-
ally, using a unique identifier (the patient’s health and care
number) to the health card registration system which contains
information on vital events such as deaths. We assigned the fol-
lowing to each CDI case based on the individual’s postcode of
residence: settlement of individuals which was classified into
urban, intermediate and rural, using the Northern Ireland
Statistics and Research Agency (NISRA) classification of settle-
ments in NI, and the NI multiple deprivation measure 2010
(a composite measure of deprivation based on 52 indicators),
which was used to assign a deprivation quintile ranging from
most (1) to least deprived (5). We also identified case fatality
(30-day all cause and CDI-specific).
Case definition
All CDI-onset categories were assigned according to the patient’s
location at the time the specimen was taken, which was used as a
proxy indicator for date of symptom onset. The case was further
categorised into either HA or CA to determine where the infec-
tion was likely acquired (Fig. 1).
For this analysis, outpatients, assessment and emergency
patients, day patients, psychiatric inpatient and regular attenders
were excluded (n = 64, Fig. 1) because of a lack of information
regarding each individual’s healthcare contact to accurately clas-
sify their association.
Microbiology
Microbiological diagnosis of CDI was carried out according to
current UK Department of Health guidelines [17] in medical
laboratories accredited by the UK Accreditation Service. In
brief, a two-stage algorithm used screening by either glutamate
dehydrogenase enzyme immunoassay or molecular (PCR) testing
to detect CDI, followed by toxin detection using enzyme
immunoassay in screen-positive specimens. C. difficile strains
were isolated from positive clinical specimens according to UK
Standards for Microbiology Investigations methods [18]. Toxin
gene detection and ribotyping of CDI isolates was done as
described previously [19]. Double infections were defined as a
CDI with separate ribotypes and assumed both ribotypes were
present in similar amounts.
Analytical strategy
For the first part of the analysis, we analysed trends, socio-
demographic factors, case fatality and ribotype for all individuals
aged 2 years and over with CA- (n = 1303) and HA-CDI (n =
1356).
CA-CDI incidence rates were calculated using mid-year popu-
lation estimates (NISRA) and expressed as episodes per 100 000
population per year. HA-CDI were expressed per 10 000 occupied
bed-days per year (data provided by the Hospital Information
Branch, Department of Health, NI).
Of all cases, 29% were a recurrent (new episode of infection
more than 28 days after the first positive specimen with negative
specimen between both episodes) or continuing infection (epi-
sode of infection with no negative sample within 28 days) in
the same patient, which were indistinguishable in our dataset.
This clustering denied the assumption of independence between
records and thus we examined the association between exposures
and CA-CDI using a multilevel mixed-effects logistic regression
model.
For the outcome data, we described the distribution of
ribotypes (data available for 2123/2659 (80%) individuals, 375
(14%) could not be specified and 161 (6%) could not be isolated)
for CA-CDI and HA-CDI. We also described all-cause and CDI-
specific case fatality within 30 days (data available for 2654/2659
individuals; 99.8%). For both outcomes, we tested the association
with CA-CDI compared with HA-CDI using logistic regression.
We also compared the odds of CDI-specific death in CA-CDI
using the most common ribotype as the baseline. This model
was adjusted for a linear trend in age on the logit scale.
Secondly, we conducted a retrospective case–case study com-
paring risk factors for COCA-CDI vs. COHA-CDI. As enhanced
risk factor information was only available for CO cases, this ana-
lysis was restricted to 483 COCA- and 287 COHA-CDI cases. We
compared socio-demographic factors for COCA- and COHA-
CDI and then examined the association between exposures and
COCA-CDI using logistic regression. The assumption of linearity
of the association between age and illness, on the logit scale, was
assessed by fitting more complex polynomial functions and sim-
plifying if these functions did not significantly improve the fit of
the model. To build the multivariable model, variables with P <
0.2 in the univariate analyses were added in a forward stepwise
fashion using a likelihood-ratio test at each step until all factors
were significant at a 0.05 level or were substantial confounders,
i.e. changed the odds ratio of one or more parameters remaining
in the model by more than 20%. Age and sex were included as a
priori confounders. The assumption of linearity for age was tested
again in the final multivariable model. We excluded variables
where collinearity was evident which included ‘having visited a
hospital in the 4 weeks prior to Clostridium difficile diagnosis’
which was collinear with ‘having attended an outpatient appoint-
ment in the 4 weeks prior to Clostridium difficile diagnosis’.
We again tested the assumption of independence between CO
cases using a multilevel mixed-effects logistic regression model.
The estimates from this model were similar in magnitude, direc-
tion and significance to the logistic regression model and thus the
simpler model is presented. We calculated odds ratios, 95%
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confidence intervals and likelihood ratio test P-values for both
analyses.
In 2016, cases with a positive CDI result within 4–12 weeks of
hospitalisation were classified as unknown origin (UNK) [20]
compared with COCA classification prior to 2016. To assess the
impact of this change, sensitivity analysis was conducted using
data from 2012 to 2016 but excluding the unknown cases in
2016 (5.2%, n = 25) and comparing it to the primary analysis.
Again, the estimates from both models were similar in magnitude,
direction and significance and so the 25 cases were retained in the
full analysis.
All analyses were conducted using Stata 2012 (StataCorp. 2011.
Stata Statistical Software: Release 12. College Station, TX, USA:
StataCorp LP.).
Ethical consideration
The CDI data were reported by Health and Social Care (HSC)
Trusts to PHA in its role as the body with statutory responsibility
for health protection surveillance. In this case, research ethics
approval was not required as a Data Access Agreement or equiva-
lent contract states the terms of data use. The analyses were
conducted using anonymised data. In addition, a specific Data
Access Agreement was created between PHA and the HSC
Business Services Organisation for assigned settlement, depriv-
ation and the identification of deaths of people who had CDI.
Results
Incidence trends
The overall CDI incidence was 28.9/100 000 population (2012–
2016) with rates for CA-CDI of 14.2/100 000 population and
for HA-CDI of 1.8 per 10 000 bed-days (2012–2016) (Fig. 2).
Whole cohort analysis (HA-CDI vs. CA-CDI)
CA-CDI cases were significantly younger (adjusted odds ratio
(AOR) 0.99; 95% confidence interval (CI) 0.99–1.0; P < 0.05)
than HA-CDI and had lower odds to be male (65% were female;
AOR 0.71; 95% CI 0.58–0.87; P < 0.001; Table 1).
CA-CDI cases also had higher odds to live in a rural settlement
band when compared with urban (AOR 1.5; 95% CI 1.1–2.1; P =
0.05).
Fig. 1. CDI surveillance case categories based on location and onset of symptoms highlighting the CDI population in Northern Ireland, 2012–2016. Dashed line
comprises community-onset cases used in the case–case study. CDI, Clostridium difficile infection; CO, community onset; HO, hospital onset; CA,
community-associated; HA, hospital-associated.
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Ribotype analysis
There was no difference in ribotypes between CA- and HA-CDI
(Fig. 3) and the association between ribotype and the odds of
CA-CDI was not significant (P = 0.12; data not shown).
Indeed, the proportion of the top 10 ribotypes within CA- and
HA-CDI was similar. The most prevalent ribotype for both
groups was RT078 (26% vs 24%, P = 0.36). One exception was
the prevalence of double infections which was higher for CA-
CDI cases when compared with HA-CDI cases (1.04% vs
0.47%, P < 0.05). Of note, only six individuals had RT027 during
the study period.
Case fatality
CA-CDI cases had 51% lower odds for case fatality due to all-
causes (OR 0.49; 95% CI 0.38–0.63; P < 0.0001) and 44% lower
odds for a CDI-specific death (OR 0.56; 95% CI 0.4–0.8; P <
0.001) compared with HA-CDI.
Among CA-CDI, ribotype was not overall significantly asso-
ciated with CDI-specific death within 30 days of specimen date
(P = 0.2, adjusted for age). Using ribotype RT078 as the baseline,
RT193 was seven times more likely to be associated with
CDI-specific 30-day case fatality (AOR 7; 95% CI 1.3–37; P =
0.021; Table 2).
Fig. 2. Rate of CDI per 100 000 population for community-associated (n = 1356) cases; and rate of CDI per 10 000 occupied bed-days for hospital-associated
(n = 1303) cases in Northern Ireland, by year 2012–2016.
Table 1. Descriptive epidemiology of all CDI cases by association with the community vs. hospital and univariable analysis, multilevel model analysis on a patient
level
CA-CDI
(n = 1303)
HA-CDI
(n = 1356)
OR (95% CI) P-valuea AOR (95% CI) P-valuean % n %
Age (years) Range
25th, 75th
Median
3–101
68, 86
79
4–103
70, 87
80
0.99 (0.99–1.0) 0.021 0.99 (0.99–1.0) 0.017
Sex (n = 2635) Male
Female
453
839
35
65
556
787
41
59
0.72 (0.58–0.88)
ref
0.001 0.71 (0.58–0.87)
ref
0.0007
Settlement band (n = 2619) Rural
Intermediate
Urban
303
763
220
24
59
17
282
775
276
21
58
21
1.4 (1.1–1.9)
1.3 (0.97–1.6)
ref
0.067 1.5 (1.1–2.1)
1.3 (0.96–1.6)
ref
0.05
Deprivation (n = 2619) Least
4
3
2
Most
231
241
231
300
283
18
19
18
23
22
279
249
261
256
288
21
19
20
19
22
0.85 (0.63–1.1)
0.99 (0.73–1.3)
0.91 (0.67–1.2)
1.3 (0.94–1.7)
ref
0.11 0.81 (0.59–1.1)
0.9 (0.65–1.2)
0.8 (0.58–1.1)
1.1 (0.83–1.5)
ref
0.14
aLikelihood ratio test P-value.
CA, community-associated; CDI, Clostridium difficile infection; HA, hospital-associated; OR, crude odds ratio; CI, confidence interval.
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Case–case study analysis (COCA-CDI vs. COHA-CDI)
In the univariate analysis, there was no difference in the age, sex,
settlement band or deprivation status of COCA-CDI and COHA-
CDI cases (Table 3).
COCA-CDI had 39% lower odds of having had an outpatient
appointment in the previous 4 weeks compared with COHA-CDI
(AOR 0.61; 95% CI 0.41–0.9, P = 0.01). This patient group also
had lower odds of being in a care home or hospice when com-
pared with their own home, than COHA-CDI (AOR 0.66; 95%
CI 0.45–0.98 and AOR 0.35; 95% CI 0.13–0.92, P = 0.02).
The proportions exposed to various risk factors were similar in
both COCA- and COHA-CDI (Table 3), including 18% and 20%
of both groups receiving antimicrobial therapy in the previous 28
days. Similarly, prescribing of gastric acid suppression therapy in
the community was equally high in both groups (55% vs. 58%, for
COCA and COHA, respectively).
Discussion
Our analysis of a population cohort of CA-CDI has shown that
these cases are likely to be younger, female and live in rural
areas. The most prevalent ribotype in CA- and HA-CDI continues
to be RT078. We also observed lower odds of CDI-specific death
within 30 days in CA-CDI cases. We can speculate that the
Fig. 3. The relative frequency of CA-CDI ribotypes com-
pared with HA-CDI ribotypes, in NI 2012–2016.
Table 2. Thirty-day CDI-specific mortality for CA-CDI by ribotypes and adjusted for age
CA-CDI (n = 1037)
30-day CDI-specific
mortality (n = 64)
AORa 95% CI P-valuebn %
Ribotypes 078 19 30 ref
0.2
002 9 14 1.3 0.34–4.8
014 5 7.8 1.1 0.21–5.3
015 5 7.8 0.79 0.16–3.9
005 3 4.7 0.41 0.06–2.7
020 1 1.6 0.15 0.01–3.1
023 3 4.7 0.63 0.1–4.5
193 8 13 7.0 1.3–37
001 3 4.7 1.3 0.17–10
026 1 1.6 0.64 0.03–15
Other groups 6 9.4 0.34 0.08–1.4
Double infections 1 1.6 0.56 0.02–14
aAdjusted for linear function of age.
bLikelihood ratio test P-value.
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reasons for this may include the likely higher vulnerability, frailty
and comorbidity in the inpatient hospital population. In terms of
risk factors among CO cases, this analysis has highlighted more
similarities than differences between COCA-CDI and COHA-
CDI. In both groups, we observed a high prevalence of modifiable
risk factors, such as PPI use and exposure to antibiotics, which is
known to increase the risk of CDI [7].
Our first objective was to describe the epidemiology of CA-
CDI using a population dataset. We showed that almost half of
CDI cases in NI are CA, and while the HA-CDI rate was stable
during the study period, it has decreased over the last decade
[21]. Despite this, the rate of CA-CDI was within estimates sum-
marised by one study [22] and lower when compared with
another study that used an equivalent case definition [8].
However, considering that underdiagnosis of CDI in the commu-
nity is likely [11], the burden of disease in the community might
even be greater than estimated. The biggest challenge for making
comparisons remains the difference in case definitions used as
well as the difference with denominators, such as whether rates
are presented per population or bed days [23].
Using all CDI cases, we identified that CA-CDI had higher
odds of being from a rural settlement compared with urban
and that the most prevalent ribotype is RT078, which is
commonly isolated from cattle and pigs [24, 25]. Farming is
one of the main industries in NI and despite the lack of occupa-
tional information of the patients, we hypothesise that it may be
exposures like farm or animal contact that have a role in CA-CDI
here. This has been discussed in other studies [14, 26, 27].
Our second objective was to compare both ribotype and CDI-
specific case fatality for CA-CDI. Here, with the benefit of ribo-
type data for almost all CDI cases, we showed an equal diversity
of ribotypes among CA- and HA-CDI, which has been described
previously [9, 13]. We found that RT078 [19, 26] was the most
prevalent type, which has also been observed in Scotland (19%
RT078 CA-CDI, 13% all CDI) [28]. An interesting finding was
the higher proportion of double infection in CA-CDI. Double
infections may play a role in horizontal gene transfer by exchan-
ging virulence factors between multiple ribotypes [29]. This may
pose a risk for the emergence of more virulent ribotypes. Despite
low numbers, the higher proportion of double infection in CA-
CDI warrants further investigation.
We showed that people with CA-CDI had lower odds of dying
of CDI-specific causes within 30 days of their specimen compared
with people with HA-CDI, which is consistent with a previous
study using a similar case definition [8]. We hypothesise that
the lower case fatality rates in CA-CDI may reflect these
Table 3. Risk factor analysis of CO-CDI cases by association with the community vs. hospital, univariate analysis and multivariable analysis (n = 629)
COCA-CDI
(n = 483)
COHA-CDI
(n = 287)
n % n % OR (95% CI) P-valuea AOR (95% CI) P-valuea
Age (years) (n = 770) Range
25th,75th
Median
4–101
73, 88
81
4–99
71, 87
81
1 (0.995–1.02) 0.3 1 (0.99–1.02) 0.16
Sex (n = 762) Male
Female
164
315
34
66
97
186
34
66
1 (0.73–1.4)
ref
0.99 0.99 (0.69–1.4) 0.97
Settlement (n = 755) Rural
Intermediate
Urban
122
277
75
26
58
16
67
167
47
24
59
17
1.14 (0.71–1.8)
1.04 (0.69–1.6)
ref
0.83
Deprivation (n = 755) Least
4
3
2
Most
99
97
94
114
70
21
21
20
24
15
63
53
56
60
49
22
19
20
21
17
1.1 (0.68–1.8)
1.3 (0.78–2.1)
1.2 (0.72–1.9)
1.3 (0.82–2.2)
ref
0.78
Residence (n = 767) Care home
Hospice
Own home
189
8
283
39
1.7
59
116
13
158
40
4.5
55
0.9 (0.67–1.23)
0.34 (0.14–0.85)
ref
0.059 0.66 (0.45–0.98)
0.35 (0.13–0.92)
0.02
Antimicrobial therapy in previous 28 days (n = 646) 73 18 46 20 0.87 (0.57–1.3) 0.49
Other resident on antibiotics (n = 602) 153 41 101 44 0.90 (0.65–1.3) 0.55
Other person with diarrhoea at home (n = 703) 48 11 30 11 0.98 (0.60–1.6) 0.93
Visited hospital in previous 4 weeks (n = 598) 44 11 72 37 0.21 (0.14–0.33) <0.0001
Outpatient appointment in previous 4 weeks
(n = 640)
105 24 66 32 0.68 (0.47–0.99) 0.043 0.61 (0.41–0.9) 0.01
Travel outside NI (n = 704) 11 2.5 7 2.6 0.95 (0.36–2.5) 0.91
Contact with infant <2 years (n = 605) 8 2.1 8 3.5 0.61 (0.23–1.6) 0.33
Gastric acid suppression (n = 732) PPI
H2
PPI + H2
230
20
2
50
4.3
0.43
151
6
0
56
2.2
0
0.82 (0.6–1.1)
1.8 (0.7–5.6)
1.3b(0.1-Inf)
0.18c
aLikelihood ratio test P-value unless specified otherwise.
bMedian unbiased estimate from exact logistic regression.
cFisher’s exact P-value.
PPI, proton pump inhibitor; H2, histamine-2 receptor antagonist.
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individuals having less co-morbidity and being slightly younger
compared with HA-CDI. Indeed, RT193, which belongs to the
same clade 5 of ribotypes as RT078, was shown to pose an even
higher risk for CDI-specific death among CA-CDI when com-
pared with RT078 in our study. Increased 14-day mortality for
CDI in a hospital context has been observed for clade 5 ribotypes
previously [30].
The last objective of this study was to try and identify risk fac-
tors for COCA-CDI when compared with COHA-CDI. We
started with known risk factors for HA-CDI with a view to trying
to discount those that were not relevant in the community setting.
Our study showed that there was no difference in the odds of
COCA-CDI when we look at antibiotic prescribing. That is, in
both COCA-CDI and COHA-CDI, approximately 20% of patients
with CDI had been exposed to antibiotics (in the preceding 28
days). This contrasts with another study, which showed that anti-
microbial therapy was less frequent in CA-CDI compared with
HA-CDI, but similar to our findings at 28% [31]. There is strong
evidence that antibiotic stewardship programmes can be used to
reduce the risk of CDI [32]. Given the lack of difference between
COCA-CDI and COHA-CDI, we suggest that antibiotic steward-
ship in the community could be a focus for improvement efforts.
However, the development of targeted initiatives will require fur-
ther investigation into the type and duration of antibiotic treat-
ment, which was not available for this analysis.
Another modifiable factor which showed no difference
between COCA-CDI and COHA-CDI was the use of PPIs.
Indeed, half of patients received PPIs (50% and 56%) in the com-
munity and hospital setting. This is concerning given the poten-
tial role of PPI use in promoting CDI [33]. This has been
supported by a recent meta-analysis of PPI use and the risk of
developing CDI. The authors concluded that there was a need
to establish guidelines for the use of PPIs which may help with
the control of CDI [34]. It is clear that these guidelines would
be appropriate in both the community and hospital setting.
We found that 28% of community-onset cases of CDI were not
known to have received either antibiotics or PPIs, which has been
observed by others [22]. Possible sources could be transmission
via food, animals or other people [35], and it is possible that
some exposures were not known to those providing risk factor
information. There is increasing evidence linking CDI to environ-
mental sources including water and food [25, 36–38], but also
pets [39], farming [40] and asymptomatic carriers [35]. While
these factors were not captured in the enhanced surveillance pro-
gramme, they should be considered in the future.
This study has a number of strengths. We used a full popula-
tion cohort of CDI patients with an unbiased sample of ribotype
data and linked CDI-specific case fatality information. However,
there are a number of limitations which influence the interpret-
ation of the data. We have categorised CDI cases according to
whether or not they had a hospital admission which will under-
estimate true healthcare contact defined by contact with primary
care, secondary care (those that were not admitted) and care
homes. We felt this was the best approach to classifying cases
given the complexity of the patient journeys and the limited infor-
mation collected. Despite this limitation, our results were compar-
able with previous studies [8, 22].
The classification of the indeterminate group of unknown ori-
gin, as per latest definition by the European Centre for Disease
Prevention and Control [20], was not available for the whole data-
set as the case definition was only implemented in NI in 2016. We
did assess the impact of this and concluded that it was not
substantial. However, as the numbers of these cases were small
in 2016, future studies are needed to assess if CDI cases with
unknown origin are more likely to be similar to CA- or HA-CDI.
The risk factor data were only available for CO cases which
were not representative of the whole cohort. This means that
the findings from the case–case study cannot be extrapolated to
the whole population but must be limited to CO cases only.
This also meant that for the whole cohort analysis, we were unable
to adjust for other potential confounders, such as co-morbidities.
Our analysis of ribotype-specific case fatality was adjusted for age,
but there could be residual confounding caused, for example, by
co-morbidities, so the data should be interpreted in this context.
We described a higher proportion of infections with two ribotypes
in the community. However, these may be underestimated as
laboratory detection methods are more likely to detect the more
prominent ribotype in a double infection. Therefore, our results
on infections with two strains may under- or overestimate the
effect of a double infection on CA-CDI. This should be explored
in future studies. Nevertheless, it is difficult to assess the level of
care patients in different residence settings are receiving. Also, the
duration and type of antibiotic treatment were not available in our
study. Similarly, we identified a number of recurrent infections in
our analysis. We accounted for these using multilevel multivari-
able regression, which minimised the possibility of introducing
a selection bias by choosing one episode for each patient.
However, it is possible that individuals with recurrent infections
may differ to those with a single infection in terms of risk factors
and outcomes. We therefore recommend a further analysis to
examine risk factors and outcomes for individuals with recurrent
CDI. Finally, because of the availability of surveillance data, we
were unable to classify outpatients, assessment and emergency
patients, day patients, psychiatric inpatient and regular attenders
using our case definitions. The exclusion of these cases may
potentially introduce a selection bias; however, we feel that
because they represent a small proportion of all cases (5%), this
effect is likely to be minimal.
Conclusions
CA-CDI accounts for half of all CDI in NI. While CDI-specific
case fatality is lower in this group than in those whose infections
are likely HA, action is required to reduce the burden of prevent-
able CA-CDI. The lack of difference in the exposure to known risk
factors for CDI, particularly for modifiable exposures such as
antibiotic and PPI use, suggest these are equally important for
CA-CDI. In response to the high level of prescribing among
COCA-CDI cases, we recommend a further data linkage study
on different classes of antibiotics for possible targeted interven-
tions. Opportunities to safely reduce antibiotic and gastric acid
suppressants use should be investigated in all healthcare settings.
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